Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending March 25, 2004. The report details share repurchase activities executed in accordance with shareholder authority granted at the Annual General Meeting on May 19, 2003.
Key Financial Metrics
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity. It focuses exclusively on capital structure changes related to share buybacks.
- Repurchase 1 (March 23, 2004): 1,870,000 shares purchased at 1,062.99 pence per share.
- Repurchase 2 (March 24, 2004): 1,850,000 shares purchased at 1,061.98 pence per share.
- Treasury Holdings: Following the March 24 transaction, the company holds 5,590,000 shares in treasury.
- Shares in Issue: 5,928,931,299 shares (excluding treasury shares).
Material Changes
The primary material change is the reduction in outstanding shares and the increase in treasury stock resulting from two consecutive open market purchases. The filing does not provide comparative financial data against prior periods.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or outlook. It includes a standard disclaimer stating the announcement does not constitute an offer or solicitation to purchase securities in any jurisdiction.
Investor Verification Checklist
- Verify the total cost of the repurchases against the company's cash position in the most recent full financial report.
- Confirm the remaining share buyback authority available under the May 2003 shareholder mandate.
- Check subsequent filings for any changes to the treasury share count or further repurchase activity.